<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title40.html">
                                    Title 40
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/40CFR158.html">Part 158
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 158.2230  Toxicology.
                            </h3>
                            <p class="depth1"><em>(a)</em> General. Subpart B of this part and Sec. 158.2201 describe how  to use the table in paragraph (g) of this section to determine the  toxicology data requirements for an antimicrobial pesticide product.  Notes that apply to an individual test, including specific conditions,  qualifications, or exceptions are listed in paragraph (h) of this  section.</p><p class="depth1"><em>(b)</em> Uses. The applicant for registration must first determine  whether the use is likely to result in pesticide residues in food or  water and therefore consult the ``Food Use'' columns of the table in  paragraph (g) of this section. Generally, if the residues of the  antimicrobial result from an application to a surface or if incorporated  into a material that may come into contact with food or feed, and  residues may be expected to transfer to such food or feed, then the  ``Indirect Food Uses'' columns is to be consulted.</p><p class="depth1"><em>(c)</em> Tiering of data requirements. Applicants for registration of  antimicrobials may perform tests in a tiered fashion. After the  initially required tests are conducted, additional testing may be  required if results of the initial tests trigger the need for additional  data. Conditions that trigger the need for additional data are given in  the test notes in paragraph (h) of this section.</p><p class="depth1"><em>(d)</em> 200 parts per billion (ppb). The 200 ppb level was originally  used by the Food and Drug Administration with respect to the  concentration of residues in or on food for tiering of data requirements  for indirect food use biocides. The Agency has also adopted this same  residue level for determining toxicology data requirements for indirect  food uses of antimicrobial pesticides. The 200 ppb level is the  concentration of antimicrobial residues in or on the food item.</p><p class="depth1"><em>(e)</em> Use of OSHA standards. If EPA determines that industrial  standards, such as the workplace standards set by the Occupational  Safety and Health Administration (OSHA standards), provide adequate  protection for a particular pesticide or a particular use pattern,  additional toxicity data may not be required for that pesticide or the  use pattern.</p><p class="depth1"><em>(f)</em> Key. R = Required; CR = Conditionally required; NR = Not  required; MP = Manufacturing-use product; EP = End-use product; TGAI =  Technical grade of the active ingredient; TEP = Typical end-use product;  PAI = Pure active ingredient; PAIRA = Pure active ingredient,  radiolabeled; Choice = choice of several test substances depending on  studies required.</p><p class="depth1"><em>(g)</em> Antimicrobial toxicology data requirements table. The following  table shows the data requirements for toxicology. The test notes  applicable to the data requirements in this table appear in paragraph  (h) of this section.</p><p class="depth2">Table--Antimicrobial Toxicology Data Requirements ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</p><p class="depth2">Food uses                                          Nonfood uses                         Test substance</p><p class="depth2">-------------------------------------------------------------------------------------------------------------------------------------------</p><p class="depth2">Swimming pools,</p><p class="depth2">Guideline No.     Data requirement                         Indirect food uses                       aquatic areas, wood                                                          Test note No.</p><p class="depth2">Direct food uses     (200     Indirect food uses     preservatives,     All other nonfood          MP               EP</p><p class="depth2">ppb)             (<=200 ppb)         metal working             uses</p><p class="depth2">fluids ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</p><p class="depth2">Acute Testing ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 870.1100.........  Acute oral          R..................  R..................  R..................  R..................  R..................  MP and TGAI....  EP and TGAI....            1, 2</p><p class="depth2">toxicity--rat. 870.1200.........  Acute dermal        R..................  R..................  R..................  R..................  R..................  MP and TGAI....  EP and TGAI....         1, 2, 3</p><p class="depth2">toxicity. 870.1300.........  Acute inhalation    R..................  R..................  R..................  R..................  R..................  MP and TGAI....  EP and TGAI....            2, 4</p><p class="depth2">toxicity--rat. 870.2400.........  Primary eye         R..................  R..................  R..................  R..................  R..................  MP and TGAI....  EP and TGAI....         1, 2, 3</p><p class="depth2">irritation--rabbi</p><p class="depth2">t. 870.2500.........  Primary dermal      R..................  R..................  R..................  R..................  R..................  MP and TGAI....  EP and TGAI....         1, 2, 3</p><p class="depth2">irritation. 870.2600.........  Dermal              R..................  R..................  R..................  R..................  R..................  MP and TGAI....  EP and TGAI....      1, 2, 3, 5</p><p class="depth2">sensitization. 870.2600.........  Acute               R..................  R..................  CR.................  R..................  CR.................  TGAI...........  TGAI...........           6, 11</p><p class="depth2">neurotoxicity--ra</p><p class="depth2">t. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</p><p class="depth2">Subchronic Testing ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 870.3100.........  90-Day oral         R..................  R..................  R..................  R..................  CR.................  TGAI...........  TGAI...........    8, 9, 15, 38</p><p class="depth2">toxicity--rodent. 870.3150.........  90-Day oral         R..................  R..................  CR.................  R..................  CR.................  TGAI...........  TGAI...........          10, 15</p><p class="depth2">toxicity--nonrode</p><p class="depth2">nt. 870.3200.........  21/28-Day dermal    CR.................  CR.................  CR.................  CR.................  CR.................  TGAI...........  EP and TGAI....          12, 13</p><p class="depth2">toxicity. 870.3250.........  90-Day dermal       CR.................  CR.................  CR.................  CR.................  CR.................  TGAI...........  EP and TGAI....   7, 13, 14, 15</p><p class="depth2">toxicity. 870.3465.........  90-Day inhalation   CR.................  CR.................  CR.................  CR.................  CR.................  TGAI...........  TGAI...........   7, 15, 16, 17</p><p class="depth2">toxicity--rat. 870.6200.........  90-Day              R..................  R..................  CR.................  R..................  CR.................  TGAI...........  TGAI...........            6, 8</p><p class="depth2">neurotoxicity--ra</p><p class="depth2">t. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</p><p class="depth2">Chronic Testing ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 870.4100.........  Chronic oral        R..................  R..................  CR.................  R..................  CR.................  TGAI...........  TGAI...........      18, 19, 20</p><p class="depth2">toxicity--rodent. 870.4200.........  Carcinogenicity--t  R..................  R..................  CR.................  R..................  CR.................  TGAI...........  TGAI...........      19, 21, 22</p><p class="depth2">wo rodent</p><p class="depth2">species--rat and</p><p class="depth2">mouse preferred. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</p><p class="depth2">Developmental Toxicity and Reproduction ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 870.3700.........  Prenatal            R..................  R..................  R..................  R..................  R..................  TGAI...........  TGAI...........  23, 24, 25, 26</p><p class="depth2">developmental</p><p class="depth2">toxicity--rat and</p><p class="depth2">rabbit preferred. 870.3800.........  Reproduction and    R..................  R..................  R..................  R..................  R..................  TGAI...........  TGAI...........  26, 27, 28, 29</p><p class="depth2">fertility effects. 870.6300.........  Developmental       CR.................  CR.................  CR.................  CR.................  CR.................  TGAI...........  TGAI...........      28, 29, 30</p><p class="depth2">neurotoxicity. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</p><p class="depth2">Mutagenicity ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 870.5100.........  Reverse mutation    R..................  R..................  R..................  R..................  R..................  TGAI...........  TGAI...........          31, 32</p><p class="depth2">assay. 870.5300.........  In vitro mammalian  R..................  R..................  R..................  R..................  R..................  TGAI...........  TGAI...........          31, 33 870.5375.........   gene mutation. 870.5385.........  In vivo             R..................  R..................  R..................  R..................  R..................  TGAI...........  TGAI...........          31, 34 870.5395.........   cytogenetics. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</p><p class="depth2">Special Testing ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 870.7485.........  Metabolism and      R..................  R..................  CR.................  R..................  CR.................  PAI or PAIRA...  PAI or PAIRA...          35, 39</p><p class="depth2">pharmacokinetics. 870.7200.........  Companion animal    CR.................  CR.................  CR.................  CR.................  CR.................  NR.............  Choice.........              36</p><p class="depth2">safety. 870.7600.........  Dermal penetration  CR.................  CR.................  CR.................  CR.................  CR.................  Choice.........  Choice.........           3, 37 870.7800.........  Immunotoxicity....  R..................  R..................  R..................  R..................  R..................  TGAI...........  TGAI...........               8 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</p><p class="depth1"><em>(h)</em> Test notes. The following test notes apply to the data  requirements in the table to paragraph (g) of this section:</p><p class="depth2">1. Not required if test material is a gas or highly volatile liquid.</p><p class="depth2">2. The six end-use product (EP) acute toxicity studies are required  using the product as formulated for sale and distribution. In addition,  if the EP label has directions for diluting the product, then, the  applicant may also need to conduct certain of the acute toxicity studies  using the highest concentration labeled for dilution (i.e., the least  diluted product). The end-use dilution testing is in addition to the  testing conducted on the EP.</p><p class="depth2">3. Not required if test material is corrosive to skin or has pH less  than 2 or greater than 11.5.</p><p class="depth2">4. Data are required when the product consists of, or under  conditions of use will result in, a respirable material (e.g., gas,  vapor, aerosol or particulates).</p><p class="depth2">5. Data are required if repeated dermal exposure is likely to occur  under conditions of use.</p><p class="depth2">6. For indirect food uses <=200 ppb, and all other nonfood uses,  data are required if the neurotoxicity screen in the 90-day oral rodent  study or other data indicate neurotoxicity.</p><p class="depth2">7. The 90-day dermal toxicity study and/or 90-day inhalation  toxicity study are required if the Agency determines that dermal and/or  inhalation exposure is the primary route of exposure.</p><p class="depth2">8. All 90-day subchronic studies in the rodent can be designed to  simultaneously fulfill the requirements of the 90-day neurotoxicity and/ or immunotoxicity studies by adding separate groups of animals for  testing of neurotoxicity and/or immunotoxicity parameters.</p><p class="depth2">9. The 90-day study is required in the rodent for hazard  characterization (possibly endpoint selection) and dose-setting for the  chronic/carcinogenicity study. It is not required in the mouse, but the  Agency would encourage the applicant to conduct a 90-day range finding  study for the purposes of dose selection for the mouse carcinogenicity  study to achieve adequate dosing and an acceptable study.</p><p class="depth2">10. A 1-year non-rodent study (i.e., 1-year dog study) may be  required if the Agency finds that a pesticide chemical is highly  bioaccumulative and slowly eliminated. EPA may also require the  appropriate metabolism and pharmacokinetic studies to evaluate more  precisely bioavailability, half life, and steady state to determine if a  longer duration dog toxicity study is needed.</p><p class="depth2">11. Although the subchronic toxicity testing guidelines include  measurement of neurological endpoints, such screens do not meet the  requirement of the 90-day neurotoxicity study. For nonfood uses, if the  90-day study does not include a neurotoxicity screen, then the acute  neurotoxicity study will be required.</p><p class="depth2">12. Data are required if all of the following criteria are met:</p><p class="depth2">i. The intended use of the antimicrobial pesticide product is  expected to result in repeated dermal human exposure to the product.</p><p class="depth2">ii. Data from a 90-day dermal toxicity study are not available.</p><p class="depth2">iii. The 90-day dermal toxicity study has not been triggered.</p><p class="depth2">13. EP testing is required if the product or any component of the  product may increase dermal absorption of the active ingredient(s) or  increases its toxic or pharmacologic effects, as determined by testing  using the TGAI or based on available information about the toxic effects  of the product or its components.</p><p class="depth2">14. Data are required if the active ingredient in the product is  known or expected to be metabolized differently by the dermal route of  exposure than by the oral route, and a metabolite of the active  ingredient is the toxic moiety.</p><p class="depth2">15. A 90-day oral toxicity test is not required for heating,  ventilation, air conditioning, and refrigeration systems (collectively  referred to as HVAC&R;). Instead, two 90-day toxicity tests, one by the  dermal route and one by the inhalation route are required.</p><p class="depth2">16. Data are required if there is the likelihood of significant  repeated inhalation exposure to the pesticide as a gas, vapor, or  aerosol.</p><p class="depth2">17. Based on estimates of the magnitude and duration of human  exposure, studies of shorter duration, e.g.,   21- or 28-days, may be sufficient to satisfy this requirement. The prime  consideration in determining the appropriateness of a shorter duration  study is the likely period of time for which humans will be exposed.</p><p class="depth2">18. Based on the positive results of the acute or 90-day  neurotoxicity studies, or on other data indicating neurotoxicity, a  chronic neurotoxicity study (i.e., a chronic study with additional  neurotoxicity evaluations) may be required to provide information about  potential neurotoxic effects from long-term exposures.</p><p class="depth2">19. Studies which are designed to simultaneously fulfill the  requirements of both the chronic oral and carcinogenicity studies (i.e.,  a combined study) may be conducted.</p><p class="depth2">20. For indirect food uses <=200 ppb, and all other nonfood uses,  data are required if either of the following criteria are met:</p><p class="depth2">i. The use of the pesticide is likely to result in repeated human  exposure over a considerable portion of the human lifespan; or</p><p class="depth2">ii. The use requires that a tolerance, tolerance exemption, or food  additive regulation or clearance be established.</p><p class="depth2">21. For indirect food uses <=200 ppb, and all other nonfood uses,  data are required if any of the following criteria, are met:</p><p class="depth2">i. The use of the pesticide is likely to result in significant human  exposure over a considerable portion of the human life span which is  significant in terms of frequency, time, duration, and/or magnitude of  exposure.</p><p class="depth2">ii. The use requires that a tolerance, tolerance exemption, or food  additive regulation or clearance be established.</p><p class="depth2">iii. The active ingredient, metabolite, degradate, or impurity:</p><p class="depth2">A. Is structurally related to a recognized carcinogen;</p><p class="depth2">B. Causes mutagenic effects as demonstrated by in vitro or in vivo  testing; or</p><p class="depth2">C. Produces a morphologic effect in any organ (e.g., hyperplasia,  metaplasia) in subchronic studies that may lead to a neoplastic change.</p><p class="depth2">22. If the requirement for a carcinogenicity study in any species is  modified or waived for any reason, then a subchronic 90-day oral study  in the same species may be required.</p><p class="depth2">23. Testing in two species is required for all uses.</p><p class="depth2">24. The oral route, by oral intubation, is preferred, unless the  chemical or physical properties of the test substance, or the pattern of  human exposure, suggest a more appropriate route of exposure.</p><p class="depth2">25. Additional testing by other routes of exposure may be required  if the pesticide is determined to be a prenatal developmental toxicant  after oral dosing.</p><p class="depth2">26. The developmental toxicity study in rodents may be combined with  the two-generation reproduction study in rodents by using a second  mating of the parental animals in either generation. Protocols must be  approved by the Agency prior to the initiation of the study.</p><p class="depth2">27. A two-generation reproduction study is required.</p><p class="depth2">28. An information-based approach to testing is preferred, which  utilizes the best available knowledge on the chemical (hazard,  pharmacokinetic, or mechanistic data) to determine whether a standard  guideline study, an enhanced guideline study, or an alternative study  should be conducted to assess potential hazard to the developing animal.  Applicants must submit any alternative proposed testing protocols and  supporting scientific rationale to the Agency. Protocols must be  approved by the Agency prior to the initiation of the study.</p><p class="depth2">29. The use of a combined two-generation reproduction/developmental  neurotoxicity study that utilizes the two-generation reproduction study  in rodents as a basic protocol for the addition of other endpoints or  functional assessments in the immature animal is encouraged.</p><p class="depth2">30. A DNT study is required using a weight-of-evidence approach  when:</p><p class="depth2">i. The pesticide causes treatment-related neurological effects in  adult animal studies (i.e., clinical signs of neurotoxicity,  neuropathology, functional or behavioral effects).</p><p class="depth2">ii. The pesticide causes treatment-related neurological effects in  developing animals, following pre- or post-natal   exposure (i.e., nervous system malformations or neuropathy, brain weight  changes in offspring, functional or behavioral changes in the  offspring).</p><p class="depth2">iii. The pesticide elicits a causative association between exposures  and adverse neurological effects in human epidemiological studies.</p><p class="depth2">iv. The pesticide evokes a mechanism that is associated with adverse  effects on the development of the nervous system (i.e., structure- activity-relationship (SAR) to known neurotoxicants, altered  neuroreceptor or neurotransmitter responses).</p><p class="depth2">31. To facilitate the weight-of-evidence determination for the  pesticide's mutagenicity, in addition to those specifically listed in  this table, the Agency requires submission of other mutagenicity test  results that may have been performed. A reference list of all studies  and papers known to the applicant concerning the mutagenicity of the  test chemical must be submitted with the required studies.</p><p class="depth2">32. Due to the nature of antimicrobials, if testing with bacterial  strains has not been conducted, then testing using a mammalian cell  assay such as the mouse lymphoma TK assay is  preferred. If reverse mutation assay testing with bacterial strains has  already been conducted, and the testing was conducted at levels that did  not cause toxicity to the bacterial strains tested, then the applicant  may submit the study to fulfill this data requirement.</p><p class="depth2">33. For the in vitro mammalian gene mutation study, there is a  choice of assays using either mouse lymphoma L5178Y cell thymidine  kinase (tk) gene locus, maximizing assay conditions for small colony  expression and detection; Chinese hamster ovary (CHO) or Chinese hamster  lung fibroblast (v79) cells, hypoxanthine-guanine phosphoribosyl  transferase (hgprt) gene locus, accompanied by an appropriate in vitro  test for clastogenicity; or CHO cells strains AS52, xanthine-guanine  phosphoribosyl transferase (xprt) gene locus.</p><p class="depth2">34. There is a choice of assays, but the micronucleus rodent bone  marrow assay is preferred; the rodent bone marrow assays using metaphase  analysis (aberrations) are acceptable.</p><p class="depth2">35. Data are required when chronic toxicity or carcinogenicity  studies are also required.</p><p class="depth2">36. Data is required if the product label directs that it be applied  to domestic animals, such as cats, dogs, cattle, pigs, and horses.</p><p class="depth2">37. In the absence of dermal absorption data or a repeated dose  dermal toxicity study, the assumption of 100 percent dermal absorption  would be used in a risk assessment to determine if a dermal penetration  study is required, and to identify the doses and duration of exposure  for which dermal absorption is to be quantified.</p><p class="depth2">38. Required for nonfood uses, if oral exposure could occur.</p><p class="depth2">39. Data may be required if significant adverse effects are seen in  available toxicology studies and these effects can be further elucidated  by metabolism and pharmacokinetics studies.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
